Literature DB >> 23831250

Possible effect of corticoids on hemiplegic attacks in severe hemiplegic migraine.

Iciar Sánchez-Albisua1, Martin Schöning, Karin Jurkat-Rott, Holger Lerche.   

Abstract

BACKGROUND: Sporadic and familial hemiplegic migraines are rare paroxysmal disorders characterized by transient hemiparesis and headache. The distinction is based on whether other family members are affected. In 50% of cases, these migraines are caused by CACNA1 A missense mutations. PATIENTS: We describe a boy with a particularly severe phenotype and a de novo R1349Q mutation of the CACNA1 A gene.
RESULTS: The patient suffered from early-onset profound mental retardation, epileptic seizures, cerebellar ataxia, and progressive cerebellar atrophy. He experienced prolonged attacks of migraine with hemiparesis, seizures, altered consciousness, and fever resulting from minor head traumas. A prolonged hemiplegic attack improved following a 5-day treatment of 100 mg/d methylprednisolone.
CONCLUSION: R1349Q mutation of the CACN1 A gene may be associated with a severe phenotype. Corticoids might be beneficial in prolonged hemiplegic attacks.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CACNA1A gene; corticoids; hemiplegic; mental retardation; migraine

Mesh:

Substances:

Year:  2013        PMID: 23831250     DOI: 10.1016/j.pediatrneurol.2013.04.011

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  2 in total

Review 1.  The electrophysiological footprint of CACNA1A disorders.

Authors:  Elisabetta Indelicato; Iris Unterberger; Wolfgang Nachbauer; Andreas Eigentler; Matthias Amprosi; Fiona Zeiner; Edda Haberlandt; Manuela Kaml; Elke Gizewski; Sylvia Boesch
Journal:  J Neurol       Date:  2021-02-05       Impact factor: 4.849

2.  Longitudinal MRI brain findings in the R1349Q pathogenic variant of CACNA1A.

Authors:  Chang Y Ho; Harrison L Love; Deborah K Sokol; Laurence E Walsh
Journal:  Radiol Case Rep       Date:  2021-03-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.